In line with this hypothesis, novel low-glutaminase asparaginase variants have been developed on the backbone of the FDA-approved Erwinia chrysantemi L-asparaginase: the variants displayed strong anti-T-ALL and -B-ALL activity, while exhibiting reduced acute toxicity features [238]. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.